Clinical Pharmacology K12 Training Program

临床药理学K12培训项目

• 批准号: 10749592
• 负责人: TRACY A GLAUSER
• 金额: $ 29.7万
• 依托单位: CINCINNATI CHILDRENS HOSP MED CTR
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-01 至 2028-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10749592
• 关键词: Active Learning; Appointment; Area; Award; Child; Childhood; Clinical Pharmacology; Collaborations; Competence; Congresses; Development; Drug toxicity; Educational process of instructing; Environment; Faculty; Fellowship; Funding; Grant; Health; Healthcare; K-Series Research Career Programs; Knowledge; Leadership; Manuscripts; Medical center; Mentored Clinical Scientist Development Program; Mentors; Mentorship; Outcome; Pediatric Hospitals; Pediatrics; Pharmaceutical Preparations; Pharmacogenetics; Pharmacology; Pharmacotherapy; Positioning Attribute; Research; Research Infrastructure; Research Personnel; Research Training; Resources; Site; Societies; Time; Training; Training Activity; Training Programs; Translations; United States Food and Drug Administration; United States National Institutes of Health; Universities; career development; design; drug action; effective therapy; experience; improved; leadership development; lectures; next generation; novel therapeutics; patient population; pediatric patients; personalized therapeutic; pharmacometrics; programs; responsible research conduct; skills; symposium

PROJECT SUMMARY/ABSTRACT During the past 20 years, Congress, the National Institutes of Health (NIH), and the Food and Drug Administration (FDA) have made it clear that safe drug therapy for children is a high priority. With the rapidly changing health care and research environments, it has become essential to focus on the training of the next generation of leaders in Pediatric Clinical Pharmacology who are involved in the design and conduct of hands- on drug studies in children to augment the translation of new and effective therapies for children. The proposed Cincinnati Children’s Pediatric Clinical Pharmacology K12 program aims to provide the resources for a diverse group of junior faculty to become the next leaders in Pediatric Clinical Pharmacology. This includes training in the principles of Pediatric Clinical Pharmacology to those who may never had previous clinical pharmacology experience while also facilitating the transition from fellowship to junior faculty to independent investigator for those who have had previous fellowship training in Pediatric Clinical Pharmacology. The training program we propose in this application for K12 Scholars will leverage the outstanding research infrastructure that exists within Cincinnati Children’s Hospital Medical Center and the University of Cincinnati Academic Health Center, the strong research training activities that we have built within the Cincinnati Children’s Division of Clinical Pharmacology, and the robust collaborations that our Division has developed with other Clinical Pharmacology T32 sites and Clinical Pharmacology programs throughout the nation. Through our rigorous training program, we expect Scholars to achieve the following five core competencies: 1) Foundational Knowledge and Skill in Pharmacometrics, 2) Foundational Knowledge and Skills in Pharmacogenetics, 3) In-depth Understanding of the Impact of Developmental Pharmacology Principles on Drug Action and Toxicity, 4) Ability to Conduct Studies in a Variety of Pediatric Patient Populations, and 5) Collaborative Skills in Interdisciplinary Team Research. The four pillars of training to achieve these core competencies will be focused on 1) research training, 2) responsible conduct of research, 3) teaching/research mentorship and 4) leadership and career development through both experiential learning and didactic courses with knowledge and skills to be attained and expected outcomes in each of these areas. Intended Scholar outcomes include high impact manuscripts describing research in Pediatric Clinical Pharmacology, submission of independent K career development awards or R awards, delivery of lectures and presentations on clinical pharmacology topics in local forums and national conferences, experience in mentoring trainees locally and nationally, and leadership positions in national committees in Clinical Pharmacology societies. We intend to have two junior faculty Scholars appointed at any time with the anticipated appointments being 2 to 3 years, depending on external grant funding. This program will expand the critically small pool of Pediatric Clinical Pharmacology investigators who will advance personalized therapeutics in pediatrics to improve the health outcomes of children.

项目摘要/摘要 在过去的20年中，国会，国立卫生研究院（NIH）和食品和毒品 管理（FDA）已经明确表示，针对儿童的安全药物治疗是一个重点。迅速 改变医疗保健和研究环境，专注于下一个培训已经成为必不可少的 在小儿临床药理学中产生的领导者，他们参与了动手的设计和行为 关于儿童的药物研究，以增加对儿童的新疗法的翻译。提议 辛辛那提儿童小儿临床药理学K12计划旨在为潜水员提供资源 初级教师小组将成为儿科临床药理学的下一个领导者。这包括培训 儿科临床药理学原理给那些可能从未有过临床药理学的人 经验，同时还支持从奖学金到初级教师到独立调查员的过渡 那些以前接受过小儿临床药理学奖学金培训的人。我们的培训计划 此申请中针对K12学者的提案将利用内部存在的杰出研究基础设施 辛辛那提儿童医院医疗中心和辛辛那提大学学术健康中心， 我们在辛辛那提儿童临床部门内建立的强大的研究培训活动 药理学以及我们部门与其他临床药理学开发的强大合作 全国T32站点和临床药理学计划。通过我们严格的培训计划， 我们希望学者能够实现以下五个核心能力：1） 药物计量学，2）药物遗传学的基础知识和技能，3）深入了解 发育药理学原理对药物作用和毒性的影响，4） 各种儿科患者人群，以及5）跨学科团队研究的协作技能。这 以实现这些核心能力的四个支柱将集中在1）研究培训上，2）负责 研究的进行，3）教学/研究精通和4）通过两者的领导和职业发展 体验学习和教学课程，并获得知识和技能，并获得了预期的结果 这些区域中的每一个。预期的学者成果包括描述研究的高影响手稿 小儿临床药理学，提交独立K职业发展奖或R奖，交付 关于当地论坛和民族会议的临床药理论主题的讲座和演讲 在本地和全国范围内有精神学员的经验，以及国家委员会的领导职务 临床药理学社会。我们打算随时任命两名初级学者 预计约会是2至3年，具体取决于外部赠款资金。该程序将扩展 小儿小儿临床药理学研究人员将提高个性化治疗 在儿科改善儿童的健康结果。